These findings are in keeping with recent studies showing that the administration of granulocyte colony-stimulating factor (G-CSF) reduces bacterial infections and improves survival in patients with decompensated cirrhosis without ACLF as well as in ACLF18, 19. This evidence concerns the gene CSF3 and bacterial infectious disease.